Update on Malignancy in Myositis—Well-Established Association with Unmet Needs

Opinc, Aleksandra; Makowska, Joanna

doi:10.3390/biom12010111

Cited by 17 publications

(13 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…При СИНАМ в крови определяются анти-HMGCR и анти-SRP, хотя они могут и отсутствовать. Соответственно, выделяют три серологических варианта заболевания: анти-HMGCR-позитивный, анти-SRP-позитивный и серонегативный [6,8,9,[16][17][18][19]. Титр анти-HMGCR коррелирует с тяжестью проявлений болезни [16].…”

Section: клиническая картинаunclassified

“…Лечение статин-индуцированных миопатий зависит от их типа [35]. Подходы к лечению СИНАМ базируются на отдельных клинических наблюдениях или очень небольших группах больных [19], а какие-либо рекомендации отсутствуют. Лечение СИНАМ более эффективно на ранних стадиях болезни и предполагает отмену статина и применение глюкокортикостероидов, иммуносупрессивных препаратов, внутривенного иммуноглобулина и/или ритуксимаба.…”

Section: лечениеunclassified

See 1 more Smart Citation

Diagnosis and treatment of statin-induced necrotizing autoimmune myopathy

Sumarokov¹,

Ezhov²

2022

CPT

View full text Add to dashboard Cite

Statin-induced necrotizing autoimmune myopathy (SINAM) is an exceptionally rare complication of statin therapy. SINAM belongs to the group of idiopathic inflammatory myopathies and is characterized by muscle cell necrosis and regeneration leading to muscle atrophy. Prominent lymphocytic infiltrates in muscle tissue are absent. Progressive muscle weakness in upper and lower extremities is the main clinical manifestation of SINAM. Autoimmune mechanism of pathogenesis explain the absense of therapeutic effect of statin discontinuation and the risk of relapses. Diagnosis of SINAM can be established by clinical and serologic data, muscle biopsy and the results on noninvasive methods (MRI, ultrasound). Early initiation of immunosuppressive treatment is essential to achieve the cure of SINAM.

show abstract

Section: клиническая картинаunclassified

Section: лечениеunclassified

Diagnosis and treatment of statin-induced necrotizing autoimmune myopathy

Sumarokov¹,

Ezhov²

2022

CPT

View full text Add to dashboard Cite

show abstract

“…Detection and treatment of an underlying malignancy could also lead to improvement in IIM disease activity, thereby reducing the need for prolonged immunosuppression which may increase the risk of developing or progressing the malignancy. 7 The recommendations outlined in the new IMACS guidelines may differ from established clinical practices and clinicians will need to adapt to the impending paradigm shift. The implementation of these guidelines into routine practice will therefore have implications for both clinical care and the associated health economic burden.…”

Section: Introductionmentioning

confidence: 99%

Real‐world implications of IMACS malignancy screening guidelines for idiopathic inflammatory myopathies: An evaluation of compliance and economic impact at a tertiary referral center

Teh,

Huang,

Oon

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

AimAn inaugural set of consensus guidelines for malignancy screening in idiopathic inflammatory myopathy (IIM) were recently published by an international working group. These guidelines propose different investigation strategies based on “high”, “intermediate” or “standard” malignancy risk groups. This study compares current malignancy screening practices at an Australian tertiary referral center with the recommendations outlined in these guidelines.MethodsWe conducted a retrospective analysis of newly diagnosed IIM patients. Relevant demographic and clinical data regarding malignancy screening were recorded. Existing practice was compared with the guidelines using descriptive statistics; costs were calculated using the Australian Medicare Benefit Schedule.ResultsOf the 47 patients identified (66% female, median age: 63 years [IQR: 55.5–70], median disease duration: 4 years [IQR: 3–6]), only one had a screening‐detected malignancy. Twenty patients (43%) were at high risk, while 20 (43%) were at intermediate risk; the remaining seven (15%) had IBM, for which the proposed guidelines do not recommend screening. Only three (6%) patients underwent screening fully compatible with International Myositis Assessment and Clinical Studies recommendations. The majority (N = 39, 83%) were under‐screened; the remaining five (11%) overscreened patients had IBM. The main reason for guideline non‐compliance was the lack of repeated annual screening in the 3 years post‐diagnosis for high‐risk individuals (0% compliance). The mean cost of screening was substantially lower than those projected by following the guidelines ($481.52 [SD 423.53] vs $1341 [SD 935.67] per patient), with the highest disparity observed in high‐risk female patients ($2314.29/patient).ConclusionImplementation of the proposed guidelines will significantly impact clinical practice and result in a potentially substantial additional economic burden.

show abstract

“…DM is strongly associated with various cancers [4]. However, the routine clinical use of tumor markers, including carcinoembryonic antigen (CEA), CA15-3, and CA19-9, were not elevated significantly in CAM, except CA125 [5]. Moreover, myositis-specific autoantibodies (MSAs), including anti-transcriptional intermediary factor 1-gamma (TIF1-γ), anti-nuclear matrix protein-2 (NXP-2), anti-small ubiquitin-like modifier activating enzyme (SAE) and anti-3-hydroxy-3-methylglutarylcoenzyme A reductase (HMGCR) autoantibodies, have been associated with an increased risk of cancer in IIM.…”

Section: Introductionmentioning

confidence: 99%

Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis

Huang

Liu

et al. 2022

Clin Rheumatol

View full text Add to dashboard Cite

Objectives The objective of the current study was to detect plasma profiles of inflammatory cytokines for determining potential biomarkers indicating cancer presence among the anti-TIF1-γ antibody-positive dermatomyositis (DM) patients. Methods Twenty-seven cancer-associated anti-TIF1-γ antibody-positive DM (Cancer TIF1-γ-DM) patients were compared with 20 anti-TIF1-γ antibody-positive DM patients without cancer (Non-cancer TIF1-γ-DM) and 10 healthy controls (HC). The plasma levels of 17 cytokines were determined using the Luminex 200 system. The ability of plasma VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ levels to distinguish the presence of cancer was evaluated through the area under the curve (AUC) analysis. Potential protein interactions of TIF1-γ and the five cytokines were analyzed using the STRING database. Results VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ plasma levels were significantly higher in the Cancer TIF1-γ-DM group, especially those without any anticancer treatment, than those in the non-cancer TIF1-γ-DM and HC groups. Meanwhile, anti-TIF1-γ antibody and the five cytokines could distinguish cancer presence in anti-TIF1-γ antibody-positive DM patients. The STRING network indicated that TIF1-γ potentially interacted with the cytokines. Positive correlations of VEGF-A among CCL2, IL-6, and IFN-γ and between IFN-γ and IL-6 were observed in Cancer TIF1-γ-DM patients. VEGF-A, TNF-α, CCL2, and IL-6 were positively associated with muscle-associated enzymes among the Cancer TIF1-γ-DM patients. Conclusion The present study identified VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as significant potential biomarkers indicating the presence of cancer and demonstrated a more detailed cytokine profile during diagnosis. These biomarkers could provide better screening strategies and insight into the Cancer TIF1-γ-DM pathogenesis. Key Points• VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ are potential biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis. Graphical abstract

show abstract

Update on Malignancy in Myositis—Well-Established Association with Unmet Needs

Cited by 17 publications

References 82 publications

Diagnosis and treatment of statin-induced necrotizing autoimmune myopathy

Diagnosis and treatment of statin-induced necrotizing autoimmune myopathy

Real‐world implications of IMACS malignancy screening guidelines for idiopathic inflammatory myopathies: An evaluation of compliance and economic impact at a tertiary referral center

Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis

Contact Info

Product

Resources

About